These results suggest that co-inhibition of BCR::ABL1 with BCL-2 prosurvival proteins, particularly BCL-2 and BCL-xL, kills myeloid BP-CML cells to a greater extent than their healthy counterparts. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.